Respiratory failure & ventilation
Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial
Primary result · DAFOR15 (days alive and free of oxygen support up to 15 days)Result — go to the resultMean difference - 0.65 95% CI −2.95 to 1.36Authors' conclusion
Antisense therapy designed to block the kallikrein-kinin pathway did not demonstrate clinical benefits in increasing days-alive without respiratory support at 15 days in patients with COVID-19 during the first wave in 2020.
Study context
- Population
- Hospitalised COVID-19 patients requiring supplementary oxygen, without mechanical ventilation or vasopressors, ≤10 days since symptom onset and ≤48 h of oxygen use; 13 sites in Brazil13 sites in Brazil
- Participants
- 111 patients
- Comparison
- Single subcutaneous dose of ISIS721744 vs placebo
- ISIS721744n = 56
- Placebon = 55reference
- Primary endpoint
- Days alive and free of oxygen support (DAFOR15)
- Follow-up
- Up to 15 days
Methodological detailsplacebo-controlled, double-blind, multicentre
- Placebo-controlled
- Double-blind
- Multicentre
Primary result
As reported in the abstract
DAFOR15 (days alive and free of oxygen support up to 15 days)
Mean difference
- 0.65
95% CI −2.95 to 1.36
P = 0.520
By group
Intervention vs Control
mean difference - 0.65 (95% CI −2.95 to 1.36); P = 0.520
Original publication
Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial. J Crit Care. Published 3 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →